Full therapeutic effects for weight management should be evaluated after 12 weeks at a maintenance dose (typically 10-15 mg weekly), while glycemic response for diabetes is assessed after 3-6 months on a stable dose
Ex4-d-Ala is represented as orange ribbon (backbone) and sticks (side chains, position 4 as thick stick), and GLP-1R is represented as white ribbon
Skin health: Skin elasticity, collagen density, scar reduction, wrinkle depth
Pregnancy and Breastfeeding Neither Semaglutide nor Tirzepatide is recommended for those who are currently pregnant, planning to become pregnant within the next six months, or breastfeeding , due to limited research on safety in these conditions
All women should discuss their reproductive health status, contraception, and family planning with their GP or a specialist before commencing any therapy in this drug class